Skip to Content
31

Johnson & Johnson

Courtesy of Johnson & Johnson

    A new weapon against a killer.

    Tuberculosis is an often overlooked scourge. Though it is preventable and curable, TB still kills 1.5 million people per year—300,000 more than are lost to AIDS annually—and rates as the world’s most deadly infectious disease. Thornier still is the proliferation of its drug-resistant forms (MDR- and XDR-TB) which—just as contagious, but harder to treat—have undermined global progress towards eradicating the disease. Half a million people develop drug-resistant TB each year; a UK parliamentary group in 2015 projected it will kill 75 million and cost the world $16.7 trillion over the next 35 years.

    Which is why Sirturo, a drug discovered by Johnson & Johnson in 2004 and given lightening fast approval by the FDA in December 2012, is such a big deal. The first-ever medicine approved for MDR-TB—and the first TB drug in four decades—J&J is now working with governments, physicians, and NGOs to spread the precious drug to those who need it. It’s not a blockbuster, but Sirturo is saving lives: the drug, which was added to the World Health Organization’s Essential Medicines List in 2015, has been registered in over 40 countries and used to treat more than 10,000 patients. Dr. Iqbal Master, who heads up TB care at King Dinuzulu Hospital in Durban, South Africa says Sirturo, which is used in conjunction with other meds, has “increased treatment success” in the most resistant patients.

    Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

    Company Information

    Impact Segment
    Public Health/Nutrition
    Sector
    Health Care
    Industry
    Pharmaceuticals
    CEO
    Alex Gorsky
    Websitehttp://www.jnj.com
    Employees127,100
    Company Type
    Public
    Revenues ($M) (Last Fiscal Year)$70,074
    Profits ($M) (Last Fiscal Year)$15,409
    Market Value ($M)$337,498